

FILE 'HOME' ENTERED AT 17:59:11 ON 17 MAR 2003

=> Index bioscience medicine

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.21 | 0.21 |

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 17:59:39 ON 17 MAR 2003

68 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s (APECED or AIRE) (s) (mutation? or mutant?) and polynucleotide? and (pharmaceutical (s) composition)

1 FILE BIOTECHABS

1 FILE BIOTECHDS

15 FILES SEARCHED...

29 FILES SEARCHED...

0* FILE FEDRIP

49 FILES SEARCHED...

3 FILE USPATFULL

1 FILE WPIDS

64 FILES SEARCHED...

1 FILE WPINDEX

5 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX

L1 QUE (APECED OR AIRE) (S) (MUTATION? OR MUTANT?) AND POLYNUCLEOTIDE? AND (P HARMACEUTICAL (S) COMPOSITION)

=> file hits

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 2.75 | 2.96 |

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 18:02:55 ON 17 MAR 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 18:02:55 ON 17 MAR 2003

COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'WPIDS' ENTERED AT 18:02:55 ON 17 MAR 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s l1

L2 3 FILE USPATFULL

L3 1 FILE BIOTECHDS

L4 1 FILE WPIDS

TOTAL FOR ALL FILES

L5 5 L1

=> d l5 1-5 ibib abs

L5 ANSWER 1 OF 5 USPATFULL

ACCESSION NUMBER: 2002:191539 USPATFULL
TITLE: Full-length human cDNAs encoding potentially secreted proteins
INVENTOR(S): Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2002102604 | A1 | 20020801 |
| APPLICATION INFO.: | US 2000-731872 | A1 | 20001207 (9) |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 1999-169629P | 19991208 (60) |
| | US 2000-187470P | 20000306 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | John Lucas, Ph.D., J.D., Genset Corporation, 10665 Srrento Valley Road, San Diego, CA, 92121-1609 | |
| NUMBER OF CLAIMS: | 29 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 5 Drawing Page(s) | |
| LINE COUNT: | 28061 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET **polynucleotides** and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 5 USPATFULL

ACCESSION NUMBER: 2000:174806 USPATFULL
TITLE: Chromosome 21 gene marker, compositions and methods using same
INVENTOR(S): Korenberg, Julie R., Los Angeles, CA, United States
Yamakawa, Kazuhiro, Los Angeles, CA, United States
PATENT ASSIGNEE(S): Cedar-Sinai Medical Center, Los Angeles, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 6166180 | | 20001226 |
| APPLICATION INFO.: | US 1998-48887 | | 19980326 (9) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1994-337690, filed on 9 Nov 1994, now patented, Pat. No. US 5773268 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Schwartzman, Robert A. | | |
| LEGAL REPRESENTATIVE: | Pennie & Edmonds LLP | | |
| NUMBER OF CLAIMS: | 6 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 4 Drawing Figure(s); 3 Drawing Page(s) | | |
| LINE COUNT: | 1522 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides isolated nucleic acids encoding human EHOC-1 protein and isolated receptor proteins encoded thereby. Further provided are vectors containing invention nucleic acids, probes that hybridize thereto, host cells transformed therewith, antisense oligonucleotides thereto and compositions containing, antibodies that specifically bind to invention polypeptides and compositions containing,

as well as transgenic non-human mammals that express the invention protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 5 USPATFULL

ACCESSION NUMBER: 1998:75417 USPATFULL
TITLE: Chromosome 21 gene marker, compositions and methods using same
INVENTOR(S): Korenberg, Julie R., Los Angeles, CA, United States
Yamakawa, Kazuhiro, Los Angeles, CA, United States
PATENT ASSIGNEE(S): Cedars-Sinai Medical Center, Los Angeles, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 5773268 | | 19980630 |
| APPLICATION INFO.: | US 1994-337690 | | 19941109 (8) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Low, Christopher S. F. | | |
| LEGAL REPRESENTATIVE: | Campbell & Flores LLP | | |
| NUMBER OF CLAIMS: | 19 | | |
| EXEMPLARY CLAIM: | 1,19 | | |
| NUMBER OF DRAWINGS: | 4 Drawing Figure(s); 3 Drawing Page(s) | | |
| LINE COUNT: | 1316 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides isolated nucleic acids encoding human EHOC-1 protein and isolated receptor proteins encoded thereby. Further provided are vectors containing invention nucleic acids, probes that hybridize thereto, host cells transformed therewith, antisense oligonucleotides thereto and compositions containing, antibodies that specifically bind to invention polypeptides and compositions containing, as well as transgenic non-human mammals that express the invention protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 5 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI

ACCESSION NUMBER: 1999-08659 BIOTECHDS
TITLE: New polypeptide which co-segregates in mutated form; human recombinant protein preparation by vector expression in host cell and DNA primer, for autoimmune polyendocrinopathy candidiasis dystrophy diagnosis, therapy or gene therapy
AUTHOR: Peltonen L; Aaltonen J; Bjorses P; Perheentupa J; Palotie A; Horelli-Kuitunen N; Yaspo M L; Lehrach H
PATENT ASSIGNEE: Max-Planck-Soc.; Nat.Inst.Public-Health-Helsinki
LOCATION: Berlin, Germany; Helsinki, Finland.
PATENT INFO: WO 9918197 15 Apr 1999
APPLICATION INFO: WO 1998-EP6294 2 Oct 1998
PRIORITY INFO: EP 1997-119810 12 Nov 1997; EP 1997-117154 2 Oct 1997
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 1999-287735 [24]

AN 1999-08659 BIOTECHDS

AB Human **polynucleotides** and polypeptides which co-segregate in mutated form with autoimmune polyendocrinopathy candidiasis dystrophy (**APECED**) are claimed. Also new are: a specified 2,245 bp DNA sequence encoding a specified 546 amino acid protein sequence or DNA that hybridizes to the new sequence; mutated forms of the DNA, cDNA and fragments; a DNA primer pair that hybridize to the new sequence; a vector containing the DNA; a host cell containing the vector; producing the protein by culturing the host cell; an antibody that specifically recognizes the protein; a **pharmaceutical composition**

containing the DNA; a diagnostic **composition** containing the DNA; and a method of testing for a carriership for **APECED** by detecting a **mutation** in the new DNA or by immunoassay using the new antibody. The methods can be used for diagnosis or gene therapy of **APECED** and other autoimmune diseases. (77pp)

L5 ANSWER 5 OF 5 WPIDS (C) 2003 THOMSON DERWENT
ACCESSION NUMBER: 1999-287735 [24] WPIDS
DOC. NO. NON-CPI: N1999-214896
DOC. NO. CPI: C1999-084974
TITLE: New polypeptide which co-segregates in mutated form.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): AALTONEN, J; BJOERSES, P; HORELLI-KUITUNEN, N; LEHRACH, H; PALOTIE, A; PELTONEN, L; PERHEENTUPA, J; YASPO, M
PATENT ASSIGNEE(S): (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN; (NAPU-N) NAT PUBLIC HEALTH INST
COUNTRY COUNT: 22
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|------|----------|-----------|----|----|
| WO 9918197 | A2 | 19990415 | (199924)* | EN | 77 |
| RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE | | | | | |
| W: CA JP US | | | | | |
| EP 1027435 | A2 | 20000816 | (200040) | EN | |
| R: CH DE DK FI FR GB IT LI SE | | | | | |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|------------|------|----------------|----------|
| WO 9918197 | A2 | WO 1998-EP6294 | 19981002 |
| EP 1027435 | A2 | EP 1998-952694 | 19981002 |
| | | WO 1998-EP6294 | 19981002 |

FILING DETAILS:

| PATENT NO | KIND | PATENT NO |
|------------|-------------|------------|
| EP 1027435 | A2 Based on | WO 9918197 |

PRIORITY APPLN. INFO: EP 1997-119810 19971112; EP 1997-117154
19971002; EP 1997-117398 19971008

AN 1999-287735 [24] WPIDS

AB WO 9918197 A UPAB: 19990624

NOVELTY - **Polynucleotides** and polypeptides which co-segregate in mutated form with autoimmune polyendocrinopathy candidiasis dystrophy (APECED).

DETAILED DESCRIPTION - A nucleic acid molecule (I) encoding a (poly)peptide (II) co-segregating in APECED is new, and comprises the 2245 bp sequence (given in the specification), which encodes a polypeptide of 546 amino acid (sequence given in the specification). (I) may also comprise (or is degenerate to) a nucleic acid molecule hybridizing to the 2245 bp sequence.

INDEPENDENT CLAIMS are also included for the following:

- (1) a mammalian homologue of (I);
- (2) a nucleic acid molecule deviating by at least one **mutation** from (I), where the mutated sequence co-segregates with **APECED**, and is an insertion, deletion, substitution and/or inversion. The **mutation** further results in a loss of function, or a gain of function, of (II);
- (3) a fragment of (I), (1) or (2), comprising at least 14 nucleotides;
- (4) a nucleic acid molecule which is complementary to (I), (1), (2) or (3);

- (5) a primer pair which hybridizes under stringent conditions to (I),
(1), (2), (3) or (4);
(6) a vector comprising one of the above nucleic acid molecules;
(7) a host transformed with the vector of (6);
(8) a process for producing (II), comprising culturing or raising the
host of (7), and isolating (II) for the culture or host;
(9) a compound derived from (II) which has essentially the same
three-dimensional structure;
(10) an antibody that specifically recognizes (II) or the compound of
(9);
(11) a **pharmaceutical composition** comprising (I),
or any of (1) to (10);
(12) a diagnostic composition comprising (I), or any of (1) to (10);
and
(13) a method for testing for a carriership for **APECED**, or
for a corresponding disease state, comprising testing a sample obtained
from a prospective patient or from a person suspected of carrying a
predisposition for a **mutation** in (I). The sample is optionally
tested in an immunoassay using the antibody of (10).

ACTIVITY - transcription factor or transcription associated factor.

MECHANISM OF ACTION - The protein of the invention directly or
indirectly influences transcription of a gene. The protein may associate
with vimentin fibres, perhaps as part of a docking mechanism regulating
nuclear translocation. Aggregates of the mutated protein may prevent
formation of vimentin intermediate filaments.

USE - The methods can be used to test individuals to see if they are
carriers for autoimmune polyendocrinopathy candidiasis dystrophy (APECED)
(claimed) and other autoimmune diseases. Any of the above nucleic acid
molecules can be used in gene therapy.

ADVANTAGE - Autoimmune polyendocrinopathy candidiasis dystrophy
(APECED) is a recessive disorder whose primary biochemical defect remains
elusive. The present protein, in a mutated form, co-segregates with
APECED, and may be used to identify factors involved in the development of
APECED.